Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07304817

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose other
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07304817
  • EU CT 2025-523743-35-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07304817. Randomized; single masking; primary purpose other. Start 2026-05-12 (actual); primary completion 2028-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
Acronym
COMPARE-VS
Condition
Cardiovascular Diseases
Condition
Heart Failure
Intervention (Drug)
vicadrostat / empagliflozin combination 1
Intervention (Drug)
Spironolactone (drug)
Lead sponsor
University Medical Center Groningen (class: other)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
DELPHINIUM (class: not stated)

Record details

Record id
cardio:ct-nct07304817
Content hash
92bd3c62ada05df873d0114c77e4f984718b2997408e3b8500e8c3cbe74654ed